LIT-927

Research use only, not for human use.

LIT-927 (LIT927) is the first selective, locally and orally active CXCL12 neutraligand with Ki of 267 nM for CXCL12-TR binding inhibition.

LIT-927 (LIT927) is the first selective, locally and orally active CXCL12 neutraligand with Ki of 267 nM for CXCL12-TR binding inhibition; displays excellent selectivity over other chemokines (CCL17, CCL22, CCL5 and CCL2), inhibits the increase in intracellular calcium concentration in EGFP-CXCR4+HEK cells in response to CXCL12 at 10 uM, has no effect on calcium responses triggered by either CCL17 or CCL22 on EGFP-CCR4+HEK cells, CCL5 on EGFP-CCR5+ HEK cells, or by CCL2 on EGFP-CCR2+HEK cells; reduces eosinophil recruitment in murine model of allergic airway hypereosinophilia.

——

——

LIT927

GPCR/G Protein

Chemokine Receptor

CXCL12

——

——

2172879-52-4

328.752

C17H13ClN2O3

>98% (HPLC)

DMSO: 25 mg/mL, 76.05 mM; Water: Insoluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C1N=C(C2=CC=C(Cl)C=C2)C=C(C3=CC=C(O)C(OC)=C3)N1

4-(4-Chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)pyrimidin-2(1H)-one

(-20℃)

With Ice Pack

≥ 2 years